Peptides for Cognitive Enhancement

1. The cognitive peptide category (nootropic vs neuroprotective)

"Cognitive peptide" is a loose umbrella over two distinct goals that often get blurred together in marketing. Separating them is the single most useful thing you can do before choosing one.

• Nootropic peptides aim at day-to-day performance in a healthy brain: focus, learning speed, mental stamina, calm under pressure. Semax and Selank live here. The goal is a state change you can feel during a work block, not a structural change to the brain.
• Neuroprotective and neurotrophic peptides aim at preserving or repairing neural tissue, typically in aging, injury, or disease states. Cerebrolysin lives here, and most of its real evidence comes from dementia and stroke populations, not healthy professionals. Dihexa is pitched as neurotrophic (it is described as promoting new synapses) but remains research-stage.

This distinction matters for expectations. A compound that nudges neurotransmitter tone (Semax, Selank) can produce a same-day subjective effect but does not "rebuild" anything. A compound studied for neurotrophic repair (Cerebrolysin) is tested over weeks in damaged brains and tells you very little about what it does for an already-healthy 35-year old wanting sharper focus.

The category also has an unusually heavy Russian research footprint. Semax and Selank were developed in Russia and most human data was published in Russian-language psychiatry and neurology journals. That does not make the data worthless, but it does mean fewer large, independent, Western replications than you would want for a confident claim.

2. Semax: BDNF upregulation and focus

Semax is a synthetic heptapeptide derived from a fragment of ACTH(4-10) with a Pro-Gly-Pro tail that slows its breakdown. It is the most established nootropic peptide and the focus half of the Semax/Selank combination RxPepsDirect can have compounded as a nasal spray.

Mechanism: Semax is reported to modulate brain-derived neurotrophic factor (BDNF) and the dopaminergic and serotonergic systems, which is the proposed basis for its effects on focus, learning, and mental energy. According to PubMed, the BDNF link comes largely from rodent work: one mouse study found that semax raised hippocampal and cortical BDNF, but only in animals with a cognitive-deficiency profile, not in high-performing animals (Firstova et al., 2009, PMID 20095391). That nuance matters: the upside may be largest where there is a deficit to correct, and smaller in an already-optimized brain.

What users report: alert, clean focus and reduced mental fatigue, often within hours, because it acts on fast neurotransmitter pathways rather than slow structural change. These are subjective reports, not validated cognitive-test outcomes in healthy adults.

Evidence caveat: Human Semax research is concentrated in Russian clinical literature (it carries regulatory approval there for stroke and cognitive indications) and has thin independent Western replication. Treat it as plausibly useful for focus, with honest uncertainty about effect size in healthy people.

→ Full protocol and stacking detail: Semax/Selank protocol guide

3. Selank: anxiolytic and memory

Selank is a synthetic analog of the immunomodulatory peptide tuftsin, again Russian-developed, and is the calming half of the Semax/Selank pair. Where Semax pushes focus and drive, Selank is positioned to take the edge off anxiety so that focus stays calm rather than jittery.

Mechanism: Selank is reported to modulate GABA-ergic and serotonergic signaling and to influence enkephalin metabolism, the proposed basis for an anxiolytic effect without the sedation or dependency of benzodiazepines.

Human evidence: Selank has the most actual clinical-trial data of the nootropic peptides here, though the trials are small and Russian. According to PubMed, comparative studies in generalized anxiety disorder and neurasthenia found anxiolytic effects comparable to benzodiazepines (medazepam) with added anti-asthenic and mild nootropic effects (Zozulia et al., 2008, PMID 18454096), and a 60-patient comparison reported a pronounced anxiolytic effect with a mild nootropic component that persisted about a week after the last dose (Medvedev et al., 2014, PMID 25176261). A later randomized study found Selank useful mainly as an add-on that reduced benzodiazepine side effects (Medvedev et al., 2015, DOI 10.17116/jnevro20151156133-40).

Honest read: Selank's strongest signal is anxiety relief, not memory enhancement. The "memory" framing comes from a mild nootropic effect noted alongside the primary anxiolytic outcome. If your problem is anxious overwhelm interfering with work, Selank has a real (if small) evidence base. If your goal is raw memory gains in a calm, healthy brain, the data does not support a strong claim.

→ Full protocol: Selank protocol guide

4. Dihexa: synaptogenesis (research stage)

Dihexa is an orally active, blood-brain-barrier-penetrant analog derived from angiotensin IV. It is the most hyped compound in this category and the one to be most cautious about.

The claim: Dihexa is described as promoting synaptogenesis (the formation of new synaptic connections) by activating the hepatocyte growth factor (HGF) and c-Met receptor system, with marketing copy often repeating that it is "orders of magnitude more potent than BDNF" at driving synaptic connectivity.

The reality: That potency framing traces back to preclinical (rodent and cell-culture) work, and the central synaptogenesis-and-cognition paper supporting the mechanism was subsequently retracted from the literature. There are no completed human clinical trials of Dihexa for cognition, no validated human dosing, and no human safety data. According to PubMed, the body of work is animal and in-vitro only.

What this means for you: Dihexa appears in our cognitive category as a compound a 503A pharmacy can make to a prescription, but it should be treated as genuinely experimental, not as a proven nootropic. A conservative provider may decline to prescribe it precisely because the human evidence does not exist. If you are choosing a cognitive peptide on evidence, Dihexa is the weakest pick despite being the loudest in marketing.

5. Cerebrolysin: neurotrophic complex

Cerebrolysin is different in kind from the others. It is not a single synthetic peptide but a porcine-brain-derived mixture of low-molecular peptides and amino acids, given as a series of intravenous infusions, and marketed as mimicking the body's own neurotrophic factors.

Where the evidence is: Cerebrolysin has the largest human trials in this roundup, but almost all of it is in disease, not healthy enhancement. According to PubMed, a 2019 Cochrane systematic review of Cerebrolysin in vascular dementia (six trials, 597 participants) found a beneficial effect on cognition and global function, but graded the evidence as very low quality, with high risk of bias, and concluded that any real benefit "may be too small to be clinically meaningful" (Cui et al., 2019, DOI 10.1002/14651858.CD008900.pub3). Review-level summaries of Alzheimer's and vascular dementia trials report statistically significant effects on cognitive and global measures at 10 to 30 mL doses (Allegri and Guekht, 2012, DOI 10.1358/dot.2012.48(Suppl.A).1739721), though much of this work was industry-supported.

Honest read: Cerebrolysin is the most clinically studied cognitive compound here and the least convenient. It requires IV infusion courses, its dementia evidence is real but weak by Cochrane's standard, and there is essentially no controlled data showing it sharpens a healthy person's cognition. RxPepsDirect does not offer Cerebrolysin in its formulary; it is included here for completeness because it dominates the "neurotrophic peptide" conversation.

6. Stacking cognitive peptides with NAD+ and methylene blue

The two non-peptide compounds most often discussed alongside cognitive peptides are NAD+ and low-dose methylene blue, both of which act on mitochondrial energy rather than neurotransmitter tone. The logic of a stack is to pair a "signaling" compound (Semax/Selank for focus and calm) with a "fuel" compound (NAD+ or methylene blue for cellular energy and neuroprotection).

• NAD+: A coenzyme central to mitochondrial energy production, offered as an injectable or as a nasal spray for those who want non-injectable, focus-oriented dosing. The evidence for NAD+ on cognition in healthy adults is preliminary and mechanistic, not outcome-proven.
• Methylene blue (low dose): Acts as an alternative mitochondrial electron carrier with antioxidant and neuroprotective properties at low doses. It carries hard contraindications: it is an auto-deny with G6PD deficiency (hemolytic anemia risk) and with SSRIs, SNRIs, or MAO inhibitors (serotonin syndrome risk). This is not a casual addition.

Stacking caution: The case for stacking is mostly mechanistic and anecdotal, not trial-proven, and every added compound adds interaction risk. The serotonin-pathway activity of Selank and the serotonin-syndrome risk of methylene blue are exactly why a provider, not a forum thread, should sign off on any combination. Lithium is a specific flag for Semax and Selank. Build a stack one compound at a time, with a clear reason for each, under provider oversight.

→ Background on delivery format: Peptide nasal sprays explained

7. What the evidence supports (and where it's weak)

Ranked honestly by human-evidence quality, weighting controlled human data over animal data and marketing claims:

The blunt summary: there is no cognitive peptide with strong, replicated, Western randomized-controlled-trial evidence for making a healthy brain measurably smarter. Selank has the most defensible (if small) human signal, and it is for anxiety more than memory. Everything else is either disease-only, preclinical, or both. Anyone promising dramatic, proven IQ or memory gains from these peptides is overselling.

8. Comparison: cognitive peptides vs prescription stimulants

People often arrive at cognitive peptides hoping for an Adderall alternative. The comparison is worth making explicitly, because the two categories are not interchangeable.

Cognitive peptides are not "natural Adderall." They are gentler, less proven tools that may help mild, everyday focus and stress, and they are not a treatment for a diagnosed attention disorder. RxPepsDirect does not prescribe controlled substances at all, so its formulary is non-controlled peptides only. If you have ADHD, the right path is a diagnosis and a prescriber-led plan, not a peptide swap.

9. Dosing protocols

Dosing below reflects how these compounds are typically prescribed and formulated. Your provider sets your actual protocol; this is orientation, not a directive.

• Semax/Selank nasal spray: Compounded as a combination nasal spray (2.5 mg/2.5 mg per mL), one spray in each nostril daily, about 250 mcg per spray. Often used as needed on demanding work days or in short courses rather than continuously. Because it is a nasal spray, it carries a short 30-day beyond-use date and ships in smaller per-cycle quantities.
• Dihexa: When compounded, it is a 5 mg oral capsule taken once daily, dosed in the morning to avoid sleep disruption. Given the absence of human data, this is a conservative, research-informed approach rather than a validated regimen.
• Cerebrolysin: In the published dementia trials, it is given as intravenous infusion courses (commonly 10 to 30 mL daily for a number of weeks, then repeated cycles), not as an at-home daily product. Its delivery model is the main practical barrier to casual use.

A practical rule across all three: start with the single best-evidenced option for your actual goal (Selank for anxiety-limited focus, Semax for drive), assess over a defined window, and only layer in a second compound with a clear reason. More compounds is not more cognition; it is more interaction risk.

10. Side effects and safety

The cognitive peptides are generally reported as well tolerated in the short courses studied, but "well tolerated in small short trials" is not the same as "proven safe long-term." Honest safety points:

• Semax and Selank: Generally well tolerated in Russian clinical use; the most relevant flag is lithium use, and any psychiatric medication should be disclosed to your provider. Active psychosis is a contraindication. No long-horizon safety trials exist.
• Dihexa: No human safety data at all. Limited long-term data, not for those with active psychosis, and every psychiatric medication should be reviewed with a provider before considering it. This is the highest-uncertainty option.
• Methylene blue (if stacked): Hard auto-deny rules apply: G6PD deficiency (hemolytic anemia risk) and concurrent SSRIs, SNRIs, or MAO inhibitors (serotonin syndrome risk). This is the most dangerous interaction surface in the whole cognitive category.

Non-responder reality: A meaningful share of people feel little to nothing from these peptides, especially healthy adults without a baseline deficit. Subjective focus or calm can also be placebo-flavored. Build in a checkpoint: if a compound has not earned its place after a fair trial, stop it rather than stacking around it.

11. Who's a candidate

Cognitive peptides make the most sense for a narrow profile and the least sense as a shortcut around medical care:

• Reasonable fit: A healthy adult with realistic expectations who wants to trial Semax for focus or Selank for anxiety-limited concentration, under provider oversight, with the understanding that effects are subtle and unproven for big gains.
• Poor fit: Anyone seeking to self-treat ADHD or replace a prescription stimulant; anyone on lithium, SSRIs, SNRIs, or MAO inhibitors who wants to add methylene blue; anyone with active psychosis; anyone expecting Dihexa to deliver its marketing claims.
• See a clinician first: New or worsening memory loss, suspected dementia, or significant anxiety or attention problems deserve a real diagnostic workup, not an over-the-internet peptide. These compounds are not a substitute for evaluation of an underlying condition.

For broader context on how peptide therapy works and how candidacy is assessed, see our peptide therapy overview.

12. How the prescription pathway works

The prescribable cognitive peptides here (the Semax/Selank nasal spray, and Dihexa where a provider is willing) follow the same two-party telehealth path RxPepsDirect uses for everything:

1. Online intake. Complete a structured health history, including psychiatric medications, lithium use, G6PD status if methylene blue is on the table, and your cognitive goals. No in-person visit required.
2. Provider review. A licensed provider reviews your intake and decides what, if anything, is appropriate. For research-stage compounds like Dihexa, a provider may decline, and that is a feature, not a bug.
3. Prescription and fill. RxPepsDirect writes the prescription only. Optimal Balance Pharmacy, a licensed 503A compounding pharmacy, fills it, collects the medication payment at wholesale, and ships it. Injectable formats ship pre-reconstituted, FedEx overnight, in a reusable cooled travel case. Nasal sprays carry a short 30-day beyond-use date.
4. Two separate charges. RxPepsDirect bills a flat $39 medical visit fee for the provider review and prescription. The medication cost is billed separately by Optimal Balance Pharmacy. As a reference, the compounded Semax/Selank nasal spray runs $150 per spray and Dihexa runs from $3.50 per capsule at the pharmacy.

RxPepsDirect serves patients in 28 U.S. States. Eligibility is confirmed at intake.